ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ZBIO vs TRAX // FORWARD P/E MULTIPLE

Zenas BioPharma Inc. (NASDAQ) VS. First Tracks Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ZBIO 1 — TRAX 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZBIO VS. TRAX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ZBIO TRAX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -9.19% -7.53% -1.66 TRAX /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 100.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.79 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 ZBIO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.3 65.8 -13.47 TRAX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.87B $1.90B -$25.8M TRAX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ZBIO REV TRAX REV ZBIO GROSS % TRAX GROSS % ZBIO FCF TRAX FCF
FY 2025 $10.0M $0 — — -$172.4M -$143.0M
FY 2024 $5.0M $0 — — -$119.8M -$126.2M
FY 2023 $50.0M — — — -$30.5M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZBIO // BETA —
TRAX // BETA —